

Lecanemab Drug

October 1, 2025 • vajiramandravi.com



Lecanemab Drug Latest News

Recently, Australia approved Lecanemab drug for early Alzheimer's diseases.

About Lecanemab Drug

- It is a **monoclonal antibody drug** to treat **early stages of Alzheimer's**.
- It is designed to slow early Alzheimer's progression by **targeting amyloid proteins** in the brain.
- It was developed to tackle the **causes of Alzheimer's disease** rather than only relieving the symptoms.

Working of Lecanemab Drug

- It uses **antibodies to recognise amyloid** in the brain and works with the brain's immune cells to clear amyloid protein build-up from the brains of people living with early-stage Alzheimer's disease.
- These amyloid protein build-ups are thought to be toxic to brain cells, causing them to get sick and eventually die, leading to the symptoms of Alzheimer's disease.
- Lecanemab is **given to patients intravenously**, which means into a vein through a drip bag.

- Recent clinical trials show a **27 per cent reduction in disease progression**.
- **Issues with** : High cost and potential side effects, including brain swelling, limit its accessibility and raise safety concerns.

What is Alzheimer's Disease?

- Alzheimer's disease is a brain disorder that **slowly destroys memory and thinking skills** and, eventually, the ability to carry out the simplest tasks.
- It is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life.
- Alzheimer's disease accounts for 60-80% of dementia cases.
- It involves parts of the brain that control thought, memory, and language.
- The condition usually **affects people aged 65 years and over**, with only 10% of cases occurring in people younger than this

Source: DTE

Source: <https://vajiramandravi.com/current-affairs/what-is-lecanemab/>

© Vajiram & Ravi. For personal use only.